DelveInsight’s, “Advanced Cervical Cancer Pipeline Insight” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Advanced Cervical Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Advanced Liver Cancer Treatment Landscape. Click here to read more @ Advanced Liver Cancer Pipeline Outlook

 

Key Takeaways from the Advanced Cervical Cancer Pipeline Report

• In January 2025:- Merck Sharp & Dohme LLC:- The purpose of this study is to evaluate the efficacy and safety of pembrolizumab plus concurrent chemoradiotherapy compared to placebo plus concurrent chemoradiotherapy in participants with locally advanced cervical cancer. The primary hypotheses are that pembrolizumab plus concurrent chemoradiotherapy is superior to placebo plus concurrent chemoradiotherapy with respect to progression-free survival and overall survival.
• In January 2025:- AstraZeneca:- A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-centre, Global Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based, Concurrent Chemoradiation Therapy (eVOLVE-Cervical). Women with locally advanced cervical cancer will be randomized in a 1:1 ratio to receive treatment with Volrustomig or Placebo.
• In January 2025:- DualityBio Inc.:- This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a study. Phase 1 adopts the standard “3+3” design to identify: the MTD and/or RP2D of DB-1310 as monotherapy, the RCD_A of DB-1310 in combination with trastuzumab and the RCD_B of DB-1310 in combination with Osimertinib; Phase 2a is a dose expansion phase to confirm the safety, tolerability and explore efficacy in selected malignant solid tumors treated with DB-1310 as monotherapy or in combination with trastuzumab or in combination with Osimertinib.
• In January 2025:- RAPT Therapeutics Inc.:- The study will be conducted in 2 parts, a dose-escalation phase (Part 1) and a cohort expansion phase (Part 2). In Part 1 of the study, subjects will be enrolled in sequential cohorts treated with successively higher doses of FLX475 as monotherapy or in combination with pembrolizumab. In Part 2 of the study, subjects will be initially enrolled in Stage 1 of parallel expansion cohorts of FLX475 as monotherapy or in combination with pembrolizumab.
• In January 2025:- Amgen:- The primary objective of Parts 1 and 2 of this study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of AMG 193 alone and in combination with docetaxel in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors.
• DelveInsight’s Advanced Cervical Cancer pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Advanced Cervical Cancer treatment.
• The leading Advanced Cervical Cancer Companies such as AstraZeneca, GlaxoSmithKline, Advaxis, Bristol-Myers Squibb, Innovent Biologics, Shanghai Henlius Biotech, Biocad, Genexine, Inc., Merck KGaA, Zeria Pharmaceutical, ISA Pharmaceuticals, Agenus Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Vaccibody AS, Fujifilm Pharmaceuticals U.S.A., Inc., NETRIS Pharma,CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Xencor, Inc., Sotio a.s., Andes Biotechnologies, and others.
• Promising Advanced Cervical Cancer Pipeline Therapies such as Durvalumab, Cisplatin, Carboplatin, IBI310, and others.

 

Stay informed about the cutting-edge advancements in Advanced Cervical Cancer treatments. Download for updates and be a part of the revolution in cancer care @ Advanced Cervical Cancer Clinical Trials Assessment

 

Advanced Cervical Cancer Emerging Drugs Profile

• Imfinzi (durvalumab): AstraZeneca

Imfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumour’s immune-evading tactics and releasing the inhibition of immune responses. Imfinzi is the only approved immunotherapy in the curative-intent setting of unresectable, Stage III non-small cell lung cancer (NSCLC) in patients whose disease has not progressed after chemoradiotherapy, and is the global standard of care in this setting based on the PACIFIC Phase III trial. Imfinzi is also approved in the US, EU, Japan, China and many other countries around the world for the treatment of extensive-stage small cell lung cancer based on the CASPIAN Phase III trial. As part of a broad development programme, Imfinzi is being tested as a single treatment and in combinations with other anti-cancer treatments for patients with small cell lung cancer, NSCLC, bladder cancer, several gastrointestinal cancers, ovarian cancer, endometrial cancer and other solid tumours. Currently, it is in Phase III stage of clinical trial evaluation to treat Locally Advanced Cervical Cancer.

 

• Dostarlimab: GlaxoSmithKline

Dostarlimab is a humanised PD-1 monoclonal antibody that binds with high affinity to the PD-1 receptor and blocks its interaction with the ligands PD-L1 and PD-L2. Currently, it is in Phase II stage of clinical trial evaluation to treat Locally Advanced Cervical Cancer.

 

• Andes 1537: Andes Biotechnologies

Andes-1537, a proprietary antisense oligonucleotide designed by Andes Biotechnology, is the Company’s most advanced investigational drug candidate and the first to enter a human clinical study. It targets a novel non-coding mitochondrial RNA (ncmtRNA) and has demonstrated antineoplastic activity in preclinical studies. Upon administration, Andes-1537 binds to a specific ncmtRNA, inducing cell cycle arrest and apoptosis of cancer cells. Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Cervical Cancer.

 

Learn more about Advanced Cervical Cancer Drugs opportunities in our groundbreaking Advanced Cervical Cancer Research and development projects @ Advanced Cervical Cancer Unmet Needs

 

Advanced Cervical Cancer Companies

AstraZeneca, GlaxoSmithKline, Advaxis, Bristol-Myers Squibb, Innovent Biologics, Shanghai Henlius Biotech, Biocad, Genexine, Inc., Merck KGaA, Zeria Pharmaceutical, ISA Pharmaceuticals, Agenus Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Vaccibody AS, Fujifilm Pharmaceuticals U.S.A., Inc., NETRIS Pharma,CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Xencor, Inc., Sotio a.s., Andes Biotechnologies, and others.

 

Advanced Cervical Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.

 

Advanced Cervical Cancer Pipeline Products have been categorized under various Molecule types such as-

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

 

Discover the latest advancements in Advanced Cervical Cancer treatment by visiting our website. Stay informed about how we’re transforming the future of oncology @ Advanced Cervical Cancer Market Drivers and Barriers, and Future Perspectives

 

Scope of the Advanced Cervical Cancer Pipeline Report

• Coverage- Global
• Advanced Cervical Cancer Companies- AstraZeneca, GlaxoSmithKline, Advaxis, Bristol-Myers Squibb, Innovent Biologics, Shanghai Henlius Biotech, Biocad, Genexine, Inc., Merck KGaA, Zeria Pharmaceutical, ISA Pharmaceuticals, Agenus Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Vaccibody AS, Fujifilm Pharmaceuticals U.S.A., Inc., NETRIS Pharma,CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Xencor, Inc., Sotio a.s., Andes Biotechnologies, and others.
• Advanced Cervical Cancer Pipeline Therapies- Durvalumab, Cisplatin, Carboplatin, IBI310, and others.
• Advanced Cervical Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Advanced Cervical Cancer Therapeutics Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

For a detailed overview of our latest research findings and future plans, read the full details of Advanced Cervical Cancer Pipeline on our website @ Advanced Cervical Cancer Emerging Drugs and Companies

 

Table of Content

1. Introduction
2. Executive Summary
3. Advanced Cervical Cancer: Overview
4. Advanced Cervical Cancer Pipeline Therapeutics
5. Advanced Cervical Cancer Therapeutic Assessment
6. Advanced Cervical Cancer – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Advanced Cervical Cancer Collaboration Deals
9. Late Stage Products (Phase III)
10. Durvalumab: AstraZeneca
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. Dostarlimab: GlaxoSmithKline
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. Andes 1537: Andes Biotechnologies
17. Drug profiles in the detailed report…..
18. Inactive Products
19. Advanced Cervical Cancer Key Companies
20. Advanced Cervical Cancer Key Products
21. Advanced Cervical Cancer- Unmet Needs
22. Advanced Cervical Cancer- Market Drivers and Barriers
23. Advanced Cervical Cancer- Future Perspectives and Conclusion
24. Advanced Cervical Cancer Analyst Views
25. Advanced Cervical Cancer Key Companies
26. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/surgical-mask-respirator-market